Consistent with the study of Lim et al (46), which has demonstrated that elevated FTO exists in the livers of NASH patients and rodent NASH model and suppression of FTO alleviates palmitic acid-induced lipotoxicity, we also found both NASH induced by HFD and chronic hepatic inflammation induced by chemicals upregulated the expression of FTO. The gene discussed is FTO; the disease is metabolic dysfunction-associated steatohepatitis.